晚期结外NK/T细胞淋巴瘤首次完全缓解后 upfront 自体干细胞移植的多中心回顾性研究
该多中心回顾性研究纳入2006至2023年中国14家中心107例一线治疗后达首次完全缓解(CR1)的III-IV期结外NK/T细胞淋巴瘤(NKTCL)患者,36%接受upfront自体干细胞移植(ASCT)巩固。中位随访39.8个月,ASCT组3年无进展生存(PFS)和总生存(OS)均显著优于非ASCT组,但校正基线预后指数(PINK)、化疗类型和局部放疗后,ASCT仅独立预测更好PFS而非OS。
要点
- 晚期NKTCL达CR1后upfront ASCT可显著改善3年PFS(78.2% vs 54.6%)和3年OS(86.0% vs 68.9%)。
- 多因素校正后upfront ASCT仅独立预测更好PFS(HR=0.37,95%CI 0.15-0.88),与OS无独立关联。
- 倾向性评分匹配后upfront ASCT仍与更好PFS显著相关,但与OS无关。
核心结论
- 真实世界数据显示,晚期NKTCL达CR1后upfront ASCT可延长PFS,但对OS的影响尚不明确。
研究设计与样本
- 多中心回顾性研究,纳入2006至2023年中国14家中心107例III-IV期NKTCL且一线治疗后达CR1的患者。
- 87%患者接受非蒽环类方案一线化疗,38例(36%)在CR1时接受upfront ASCT巩固。
主要发现
- 中位随访39.8个月,ASCT组与非ASCT组3年PFS分别为78.2%与54.6%(p=0.005),3年OS分别为86.0%与68.9%(p=0.04)。
- 非蒽环类化疗亚组(N=93)中,ASCT与更好PFS显著相关(3年PFS 77.6% vs 59.3%,p=0.025),但与OS无关(3年OS 85.6% vs 74.8%,p=0.164)。
- 多因素分析校正PINK、一线化疗类型和局部放疗后,upfront ASCT独立预测更好PFS(HR=0.37,95%CI 0.15-0.88,p=0.025),但不预测OS。
- 倾向性评分匹配分析后,upfront ASCT仍与更好PFS显著相关,但与OS无关。
临床怎么用
- 对于一线治疗后达CR1的晚期NKTCL患者,可考虑upfront ASCT以改善PFS,但需权衡其对OS获益的不确定性。
局限性
- 回顾性研究设计可能存在选择偏倚,且OS获益在多因素校正和倾向性评分匹配后未达显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to evaluate the effect of upfront autologous stem cell transplantation (ASCT) on the prognosis in patients with advanced-stage extra-nodal NK/T-cell lymphoma (NKTCL) achieving first complete remission (CR1) after frontline therapy. To this end, we retrospectively reviewed data from patients diagnosed with stage III or IV NKTCL who achieved CR1 after frontline treatment between 2006 and 2023 at 14 medical centers in China. A total of 107 patients were included in this study. The majority of patients (87%) received non-anthracycline-based first-line chemotherapy, and 38 (36%) received upfront ASCT consolidation at the time of CR1. With a median follow-up time of 39.8 months, progression-free survival (PFS) and overall survival (OS) rates were significantly better in the ASCT group than in the non-ASCT group (3-year PFS: 78.2% vs. 54.6%, p = 0.005; 3-year OS: 86.0% vs. 68.9%, p = 0.04). However, in the subgroup of patients receiving non-anthracycline-based chemotherapy (N = 93), ASCT was significantly associated with better PFS (3-year PFS: 77.6% vs. 59.3%, p = 0.025) but not with OS (3-year OS: 85.6% vs. 74.8%, p = 0.164). In multivariate analyzes, upfront ASCT was an independent predictor of better PFS (hazard ratio [HR] = 0.37, 95% confidence interval [CI]: 0.15-0.88, p = 0.025) but not OS after adjusting for baseline prognostic index of NK-cell lymphoma (PINK), types of first-line chemotherapy, and local radiotherapy. After propensity score matched analyzes, upfront ASCT remained significantly associated with better PFS but not with OS. These real-world data suggest upfront ASCT prolongs PFS in patients with advanced-stage NKTCL in CR1, yet its impact on OS remains unclear.
引用
- Hu S, Liu W, Zhao L, et al. Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study. Am J Hematol. 2026. PMID: 42475115. doi:10.1002/ajh.70415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。